GlassScriptPhysician profile
Susan Morris
NPI 1780641126
$1,150.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2021: $48.23 · 2022: $46.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $177.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $166.53 | 2019 | |
| Pfizer INC. | $125.49 | 2019-2022 | |
| Astellas Pharma US INC | $120.52 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $117.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.64 | 2019 | |
| Amarin Pharma, INC. | $72.75 | 2019 | |
| Amgen INC. | $60.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.01 | 2019 | |
| Edwards Lifesciences Corporation | $33.24 | 2021 | |
| Merck Sharp & Dohme LLC | $26.74 | 2019 | |
| Covis Pharma Gmbh | $20.67 | 2022 | |
| Circassia INC. | $14.48 | 2019 | |
| Glaxosmithkline, LLC. | $14.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.